SEATTLE, April 4, 2016 /PRNewswire/ -- Sound Pharmaceuticals, a leader in developing novel drug treatments for diseases of the inner ear, announced today that Jonathan Kil, MD, Co-Founder and Chief Executive Officer, has been invited to present at the 15th Annual Needham & Company Healthcare Conference on Wednesday, April 13th, 2016 at 11:20 a.m. EST in New York, NY.
Dr. Kil will share an update on the Company's milestone achievements from the past year, along with the strategic objectives for its research and development programs for 2016 and beyond. In addition, he will highlight some of the significant market opportunities within the field of otolaryngology, specifically, otology and neurotology.
Needham & Company's 15th Annual Healthcare Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors.
About Sound Pharmaceuticals
Sound Pharmaceuticals, Inc. (SPI) is a pioneer in otologic drug development aimed at treating sensorineural diseases of the inner ear. SPI is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss and tinnitus including ototoxicity and Meniere's disease. Sensorineural hearing loss is the third largest disease and affects 50 million Americans. SPI is a privately held biotechnology company headquartered in Seattle, WA.
Contact:
Sound Pharmaceuticals
Paul Rickey, CFO
ir@soundpharma.com
www.soundpharma.com
SOURCE Sound Pharmaceuticals